Andreas Stahl, Hidehiko Nakanishi, Domenico Lepore, Wei-Chi Wu, Noriyuki Azuma, Carlos Jacas, Robert Vitti, Aditya Athanikar, Karen Chu, Pablo Iveli, Fei Zhao, Sergio Leal, Sarah Schlief, Thomas Schmelter, Thomas Miller, Evra Köfüncü, Alistair Fielder
IMPORTANCE: Prospective long-term data after retinopathy of prematurity (ROP) treatment with anti-vascular endothelial growth factor injections vs laser therapy are scarce. The FIREFLEYE (Aflibercept for ROP IVT Injection vs Laser Therapy) next trial is prospectively evaluating the long-term efficacy and safety outcomes following ROP treatment with intravitreal aflibercept vs laser therapy. OBJECTIVE: To evaluate 2-year ophthalmic and safety outcomes after 0.4-mg aflibercept injection or laser therapy in the 24-week randomized (2:1) FIREFLEYE trial (FIREFLEYE outcomes previously reported)...
April 1, 2024: JAMA Network Open